Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The APPG on Malaria & NTDs gathered on Tuesday, March 19th in Westminster at the Houses of Parliament. Jeremy Lefroy MP welcomed Rob van der Pluijm on behalf of the Mahidol-Oxford Tropical Medicine Research Unit (MORU), the Tracking Resistance to Artemesinin Collaboration II and the Developing Triple Artemisinin-based Combination Therapies (DeTACT) Project.

Rob van der Pluijm presented encouraging findings from TRAC II trial analyses of Triple ACTs, and the preliminary launch plans for the DeTACT Project in Africa and Asia. TRACII trials recruited over 1,000 patients across Asia with uncomplicated falciparum malaria. Results suggest TACTs are safe and highly efficacious even against multi-drug resistant falciparum malaria, currently highly prevalent in parts of SE Asia.

Read more (Worldwide Antimalarial Resistance Network website)

Similar stories

Oxford vaccine reaches one billion doses released

The University of Oxford’s and our partners AstraZeneca have today announced that one billion doses of the ChAdOx1 nCov-19 coronavirus vaccine have been released, to more than 170 countries, marking a key milestone as part of the University and AstraZeneca’s joint vision to make the available to the world, on a not-for-profit basis for the world during the pandemic, and in perpetuity for low- and middle-income countries.

Research programme tackling COVID-19 variants of concern receives funding boost

A gift from the Red Avenue Foundation will enable the expansion of a major research programme aimed at rapidly identifying and interrogating emerging COVID-19 variants.

Phase I trial begins of new vaccine against the Plague

Researchers at the University of Oxford today launched a Phase 1 trial to test a new vaccine against plague.

New therapeutic targets identified in the treatment of psoriatic arthritis

Researchers identify two inflammatory-driving proteins, osteopontin and CCL2, highly expressed in psoriatic arthritis joints.

Treatment choice for rotator cuff disorders could create efficiency and savings for the NHS

A trial that evaluated the clinical and cost effectiveness of physiotherapy treatments for rotator cuff disorders suggests cost savings can be made while maintaining positive patient outcomes.